BR112015023129A2 - compostos aromáticos substituídos para o tratamento de fibrose pulmonar, fibrose hepática, fibrose da pele e fibrose cardíaca - Google Patents
compostos aromáticos substituídos para o tratamento de fibrose pulmonar, fibrose hepática, fibrose da pele e fibrose cardíacaInfo
- Publication number
- BR112015023129A2 BR112015023129A2 BR112015023129A BR112015023129A BR112015023129A2 BR 112015023129 A2 BR112015023129 A2 BR 112015023129A2 BR 112015023129 A BR112015023129 A BR 112015023129A BR 112015023129 A BR112015023129 A BR 112015023129A BR 112015023129 A2 BR112015023129 A2 BR 112015023129A2
- Authority
- BR
- Brazil
- Prior art keywords
- fibrosis
- treatment
- aromatic compounds
- substituted aromatic
- skin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
- C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798427P | 2013-03-15 | 2013-03-15 | |
| PCT/CA2014/000237 WO2014138907A1 (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015023129A2 true BR112015023129A2 (pt) | 2017-07-18 |
Family
ID=51535670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023129A BR112015023129A2 (pt) | 2013-03-15 | 2014-03-14 | compostos aromáticos substituídos para o tratamento de fibrose pulmonar, fibrose hepática, fibrose da pele e fibrose cardíaca |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9884802B2 (https=) |
| EP (1) | EP2970088B1 (https=) |
| JP (1) | JP6381557B2 (https=) |
| KR (1) | KR102303493B1 (https=) |
| CN (1) | CN105143170B (https=) |
| AR (1) | AR095427A1 (https=) |
| AU (1) | AU2014231649C1 (https=) |
| BR (1) | BR112015023129A2 (https=) |
| CA (1) | CA2905633C (https=) |
| CL (1) | CL2015002725A1 (https=) |
| DK (1) | DK2970088T3 (https=) |
| EA (1) | EA031511B1 (https=) |
| ES (1) | ES2780825T3 (https=) |
| IL (1) | IL241164B (https=) |
| MX (1) | MX375261B (https=) |
| MY (1) | MY194727A (https=) |
| NZ (1) | NZ712745A (https=) |
| PH (1) | PH12015502012A1 (https=) |
| PL (1) | PL2970088T3 (https=) |
| PT (1) | PT2970088T (https=) |
| SG (1) | SG11201507274PA (https=) |
| TW (2) | TWI742541B (https=) |
| UY (1) | UY35401A (https=) |
| WO (1) | WO2014138907A1 (https=) |
| ZA (1) | ZA201507062B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| RS60244B1 (sr) | 2013-01-15 | 2020-06-30 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| ES2785317T3 (es) * | 2014-10-10 | 2020-10-06 | Liminal Biosciences Ltd | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis |
| KR20170072352A (ko) | 2014-11-12 | 2017-06-26 | 프로메틱 파마 에스엠티 리미티드 | 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물 |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| CN117402059A (zh) | 2015-05-13 | 2024-01-16 | Ds生物制药有限公司 | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| US10046007B2 (en) * | 2015-06-24 | 2018-08-14 | Prescient Pharma, Llc | Compositions and methods for treatment of short telomere disorders |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN111343986A (zh) * | 2017-11-15 | 2020-06-26 | 加拉帕戈斯股份有限公司 | 用于治疗纤维化疾病的化合物及其药物组合物 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| US20210205253A1 (en) * | 2018-05-31 | 2021-07-08 | The Asan Foundation | Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis |
| US11820834B2 (en) | 2018-07-10 | 2023-11-21 | Novmetapharma Co., Ltd. | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease |
| MA53188A1 (fr) | 2018-10-11 | 2021-12-31 | Basf As | Composés aromatiques et leurs utilisations pharmaceutiques |
| WO2020113340A1 (en) * | 2018-12-05 | 2020-06-11 | Liminal Biosciences Limited | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome |
| EP3908668A4 (en) | 2019-01-11 | 2022-11-09 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR PREDICTING THE DECREASE IN LUNG FUNCTION IN IDIOPATHIC LUNG FIBROSIS |
| WO2020181163A1 (en) * | 2019-03-06 | 2020-09-10 | Tobira Therapeutics, Inc. | Lipid-based formulation of cenicriviroc |
| KR102140910B1 (ko) | 2019-03-28 | 2020-08-04 | 주식회사 노브메타파마 | Chp(사이클로-히스프로)를 포함하는 섬유증의 예방, 개선 또는 치료용 조성물 |
| WO2021015218A1 (ja) * | 2019-07-24 | 2021-01-28 | 国立大学法人九州大学 | 転写関連因子を標的とする線維化疾患の予防または治療 |
| CN112441916A (zh) * | 2019-08-29 | 2021-03-05 | 广东药科大学 | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 |
| JP2024512510A (ja) * | 2020-10-06 | 2024-03-19 | ファーマセウティーク・インジェニュー・インコーポレイテッド | 置換芳香族化合物及びその医薬組成物 |
| US12053467B2 (en) | 2020-12-18 | 2024-08-06 | NovMeta Pharma Co., Ltd. | Method of treating fibrosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20012434A1 (it) | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| PT2427416E (pt) * | 2009-05-04 | 2016-06-15 | Prometic Pharma Smt Ltd | Compostos aromáticos substituídos e seus usos farmacêuticos |
| MX2011011756A (es) * | 2009-05-04 | 2012-01-25 | Prometic Biosciences Inc | Sales de acido 3-pentilfenilacetico y usos farmaceuticos. |
| MX365807B (es) * | 2010-10-27 | 2019-06-14 | Prometic Pharma Smt Ltd | Compuestos y composiciones para el tratamiento del cáncer. |
| CN102070433B (zh) * | 2010-12-27 | 2013-03-27 | 桂林师范高等专科学校 | 芳香基乙酸类衍生物的制备方法 |
| TWI689490B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| KR20170072352A (ko) * | 2014-11-12 | 2017-06-26 | 프로메틱 파마 에스엠티 리미티드 | 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물 |
-
2014
- 2014-03-12 TW TW109106077A patent/TWI742541B/zh not_active IP Right Cessation
- 2014-03-12 TW TW103108714A patent/TWI689489B/zh not_active IP Right Cessation
- 2014-03-13 AR ARP140100971A patent/AR095427A1/es unknown
- 2014-03-13 UY UY0001035401A patent/UY35401A/es not_active Application Discontinuation
- 2014-03-14 ES ES14762607T patent/ES2780825T3/es active Active
- 2014-03-14 PL PL14762607T patent/PL2970088T3/pl unknown
- 2014-03-14 PT PT147626071T patent/PT2970088T/pt unknown
- 2014-03-14 JP JP2015561850A patent/JP6381557B2/ja not_active Expired - Fee Related
- 2014-03-14 NZ NZ712745A patent/NZ712745A/en not_active IP Right Cessation
- 2014-03-14 BR BR112015023129A patent/BR112015023129A2/pt not_active Application Discontinuation
- 2014-03-14 MY MYPI2015002292A patent/MY194727A/en unknown
- 2014-03-14 SG SG11201507274PA patent/SG11201507274PA/en unknown
- 2014-03-14 US US14/775,882 patent/US9884802B2/en not_active Expired - Fee Related
- 2014-03-14 WO PCT/CA2014/000237 patent/WO2014138907A1/en not_active Ceased
- 2014-03-14 MX MX2015012886A patent/MX375261B/es active IP Right Grant
- 2014-03-14 CA CA2905633A patent/CA2905633C/en active Active
- 2014-03-14 AU AU2014231649A patent/AU2014231649C1/en not_active Ceased
- 2014-03-14 EP EP14762607.1A patent/EP2970088B1/en active Active
- 2014-03-14 CN CN201480015002.6A patent/CN105143170B/zh not_active Expired - Fee Related
- 2014-03-14 KR KR1020157029285A patent/KR102303493B1/ko not_active Expired - Fee Related
- 2014-03-14 EA EA201591774A patent/EA031511B1/ru not_active IP Right Cessation
- 2014-03-14 DK DK14762607.1T patent/DK2970088T3/da active
-
2015
- 2015-09-03 IL IL241164A patent/IL241164B/en active IP Right Grant
- 2015-09-09 PH PH12015502012A patent/PH12015502012A1/en unknown
- 2015-09-15 CL CL2015002725A patent/CL2015002725A1/es unknown
- 2015-09-22 ZA ZA2015/07062A patent/ZA201507062B/en unknown
-
2017
- 2017-12-22 US US15/852,977 patent/US10450258B2/en not_active Expired - Fee Related
-
2019
- 2019-09-24 US US16/580,747 patent/US11267779B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023129A2 (pt) | compostos aromáticos substituídos para o tratamento de fibrose pulmonar, fibrose hepática, fibrose da pele e fibrose cardíaca | |
| MX2015011878A (es) | Compuestos aromaticos sustituidos y metodo relacionado para el tratamiento de la fibrosis. | |
| BR112014013661A8 (pt) | derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
| BR112015026410A2 (pt) | derivados de dolastatina 10 e auristatinas | |
| BR112015018738A2 (pt) | compostos de tetra-hidropirrolotiazina | |
| BR112013018601A2 (pt) | composto, uso de composto, composição farmacêutica, e, produto farmacêutico | |
| DOP2013000239A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso. | |
| BR112017003442A2 (pt) | compostos e métodos para inibir histona desmetilases | |
| BR112014007078A2 (pt) | composição de controle de doença de plantas e seu uso | |
| BR112014026266A2 (pt) | derivado de quinazolidinadiona | |
| BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
| MA39189A1 (fr) | Dérivés de 1h-indazole et de 1h-indole antibactériens | |
| BR112014028718A2 (pt) | derivados de hidantoína como inibidores de kv3 | |
| BRPI1014802B8 (pt) | profármacos de triptolida. | |
| BR112015031878A2 (pt) | composição farmacêutica | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| BRPI0815129B8 (pt) | composição radiofarmacêutica, e, métodos para preparação de uma composição radiofarmacêutica | |
| BR112015026967A2 (pt) | compostos fenoxietil di-hidro-1h-isoquinolina | |
| BR112012014196A2 (pt) | agente para prevenir ou melhorar a pigmentação | |
| BR112014032244A2 (pt) | composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças associadas com hiperplasia, neoplasia ou displasia, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica | |
| BR112013027395A2 (pt) | inibidores de 17alfa-hidroxilase/c17,20-liase | |
| BR112013001609A2 (pt) | composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina | |
| BR112015028075A2 (pt) | derivado de glicinamida alfa-substituída | |
| BR112017007420A2 (pt) | compostos aromáticos substituídos e composições farmacêuticas para impedir e tratar diabetes | |
| BR112015019307A8 (pt) | derivados de ácido butanóico substituído com bisfenila, seus usos, e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: PROMETIC PHARMA SMT LIMITED (CA) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |